Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.32 CAD | -0.27% |
|
-3.68% | +79.41% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -98% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.23 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.21 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+79.41% | 272M | - | ||
-3.30% | 30.09B | C | ||
+44.89% | 9.91B | C- | ||
+36.91% | 4.52B | B- | ||
-36.88% | 2.39B | C- | ||
-8.48% | 1.62B | - | C+ | |
-29.26% | 1.22B | B | ||
+6.61% | 953M | C | ||
-45.05% | 936M | - | ||
-46.72% | 732M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- VHI Stock
- Ratings Vitalhub Corp.